Anion binding mediated precipitation of a peptibody

Pharmaceutical Research

Volumn 26, Issue 1, 2009, Pages 152-160

  Saluja, Atul ^a   Crampton, Shon ^a   Kras, Eva ^b   Fesinmeyer, R Matthew ^a   Remmele Jr , Richard L ^c   Narhi, Linda O ^c   Brems, David N ^c   Gokarn, Yatin R ^a  

^a Process and Product Development   (United States)

^b SEATTLE GENETICS INC   (United States)

^c Process and Product Development   (United States)

Author keywords

Anion binding; Hofmeister effect; Protein formulation; Protein solubility; Salt induced precipitation

Indexed keywords

ANION; BASIC PROTEIN; CATION; INORGANIC SALT; PEPTIBODY A; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG FORMULATION; PRECIPITATION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN STABILITY; SOLUBILITY;

ANIONS; CIRCULAR DICHROISM; ELECTROPHORETIC MOBILITY SHIFT ASSAY; ESCHERICHIA COLI; HYDROGEN-ION CONCENTRATION; IMMUNOGLOBULIN FC FRAGMENTS; PRECIPITATION; RECOMBINANT FUSION PROTEINS; SODIUM CHLORIDE; SOLUBILITY; SPECTROSCOPY, FOURIER TRANSFORM INFRARED;

EID: 57749184562     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9722-0     Document Type: Article

References (27)

1. E. Koren L. A. Zuckerman A. R. Mire-Sluis 2002 Immune responses to therapeutic proteins in humans-clinical significance, assessment and prediction Curr. Pharm. Biotechnol 3 349 360
2. E. D. Lobo R. J. Hansen J. P. Balthasar 2004 Antibody pharmacokinetics and pharmacodynamics J. Pharm. Sci 93 2645 2668
3. A. Braun L. Kwee M. A. Labow J. Alsenz 1997 Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-a) in normal and transhenic mice Pharm. Res 14 1472 1478
4. A. S. Rosenberg. Effects of protein aggregates: An immunologic perspective. AAPS Journal. 8:Article 59: ( http://www.aaps.org ) (2006).
5. H. C. Mahler R. Muller W. Friess A. Delille S. Matheus 2005 Induction and analysis of aggregates in a liquid IgG1-antibody formulation Eur. J. Pharm. Biopharm 59 407 417
6. B. Dani R. Platz S. T. Tzannis 2007 High concentration formulation feasibility of human immunoglubulin G for subcutaneous administration J. Pharm. Sci 96 1504 1517
7. R. J. Harris S. J. Shire C. Winter 2004 Commercial manufacturing scale formulation and analytical characterization of therapeutic recombinant antibodies Drug Dev. Res 61 137 154
8. K. L. Shaw G. R. Grimsley G. I. Yakovlev A. A. Makarov C. N. Pace 2001 The effect of net charge on the solubility, activity, and stability of ribonuclease Sa Protein Sci 10 1206 1215
9. S. R. Trevino J. M. Scholtz C. N. Pace 2007 Amino acid contribution to protein solubility: Asp, Glu, and Ser contribute more favorably than the other hydrophilic amino acids in RNase Sa J. Mol. Biol 366 449 460
10. J. Liu M. D. H. Nguyen J. D. Andya S. J. Shire 2005 Reversible self-association increases the viscosity of a concentrated monoclonal antibody in aqueous solution J. Pharm. Sci 94 1928 1940
11. W. A. Eaton J. Hofrichter 1990 Sickle cell hemoglobin polymerization Adv. Protein Chem 40 63 279
12. B. L. Chen X. Wu S. J. Babuka M. Hora 1999 Solubility of recombinant human tissue factor pathway inhibitor J. Pharm. Sci 88 881 888
13. A. C. Herman T. C. Boone H. S. Lu 1996 Characterization, formulation, and stability of Neupogen (Filgrastim), a recombinant human granulocyte-colony stimulating factor Pharm. Biotechnol 9 303 328
14. B. A. Kerwin B. S. Chang C. V. Gegg M. Gonnelli T. Li G. B. Strambini 2002 Interactions between PEG and type I soluble tumor necrosis factor receptor: modulation by pH and by PEGylation at the N terminus Protein Sci 11 1825 1833
15. J. A. Durant C. Chen T. M. Laue T. P. Moody S. A. Allison 2002 Use of T4 lysozyme charge mutants to examine electrophoretic models Biophys. Chem 101-102 593 609
16. A. Dong P. Huang W. S. Caughey 1990 Protein secondary structures in water from second-derivative amide I infrared spectra Biochemistry 29 3303 3308
17. P. I. Haris F. Severcan 1999 FTIR spectroscopic characterization of protein structure in aqueous and non-aqueous media J. Mol. Catal., B Enzym 7 207 221
18. A. Dong B. Kendrick L. Kreilgard J. Matsuura M. C. Manning J. F. Carpenter 1997 Spectroscopic study of secondary structure and thermal denaturation of recombinant human factor XIII in aqueous solution Arch. Biochem. Biophys 347 213 220
19. M. van de Weert P. I. Haris W. E. Hennink D. J. Crommelin 2001 Fourier transform infrared spectrometric analysis of protein conformation: effect of sampling method and stress factors Anal. Biochem 297 160 169
20. K. D. Collins 1997 Charge density-dependent strength of hydration and biological structure Biophys. J 72 65 76
21. P. Retailleau M. Ries-Kautt A. Ducruix 1997 No salting-in of lysozyme chloride observed at low ionic strength over a large range of pH Biophys. J 73 2156 2163
22. K. D. Collins 2004 Ions from the Hofmeister series and osmolytes: effects on proteins in solution and in the crystallization process Methods 34 300 311
23. N. P. Bhatt K. Patel R. T. Borchardt 1990 Chemical pathways of peptide degradation. I. Deamidation of adrenocorticotropic hormone Pharm. Res 7 593 599
24. C. Oliyai R. T. Borchardt 1994 Chemical pathways of peptide degradation. VI. Effect of the primary sequence on the pathways of degradation of aspartyl residues in model hexapeptides Pharm. Res 11 751 758
25. E. Y. Chi S. Krishnan T. W. Randolph J. F. Carpenter 2003 Physical stability of proteins in aqueous solution: mechanism and driving forces in nonnative protein aggregation Pharm. Res 20 1325 1336
26. W. Wang 1999 Instability, stabilization, and formulation of liquid protein pharmaceuticals Int. J. Pharm 185 129 188
27. S. Kanai J. Liu T. W. Patapoff S. J. Shire 2008 Reversible self-association of a concentrated monoclonal antibody solution mediated by Fab-Fab interaction that impacts solution viscosity J. Pharm. Sci. 94 1928 1940